Methods for the use of 5'-adenosine diphosphate ribose (adpr)
AssigneeInvirsa, Inc.
InventorsRobert Shalwitz, Anna Kotsakis Ruehlmann
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for the use of 5′-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.
Claims39
A method for treating, managing, or preventing an RNA virus-related disease or condition in a patient, said method comprising administering to the patient an effective amount of 5′-adenosine diphosphate ribose (ADPR), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopologue, or polymorph thereof;
- wherein the patient has or is at risk of developing an RNA virus-related disease or condition.
A method of increasing the activity of sirtuin 6 (Sirt6) in a patient in need thereof, comprising administering to the patient an effective amount of ADPR, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopologue, or polymorph thereof.
A method for treating, managing, or preventing a disease or condition associated with Sirt6 deficiency in a patient, said method comprising administering to the patient an effective amount of ADPR, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopologue, or polymorph thereof;
- wherein the patient has or is at risk of developing a disease or condition associated with Sirt6 deficiency.
A method for treating, managing, or preventing a herpes virus-related disease or condition in a patient, said method comprising administering to the patient an effective amount of ADPR or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopologue, or polymorph thereof;
- wherein the patient has or is at risk of developing a herpes virus-related disease or condition.
A method of increasing the activity of Pax6 in a patient in need thereof, comprising administering to the patient an effective amount of ADPR, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopologue, or polymorph thereof.
A method for treating, managing, or preventing a disease or condition associated with Pax6 deficiency in a patient, said method comprising administering to the patient an effective amount of ADPR, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopologue, or polymorph thereof;
- wherein the patient has or is at risk of developing a disease or condition associated with Pax6 deficiency.
A method of increasing the concentration of p53 by inhibiting MDM2 in a patient in need thereof, comprising administering to the patient an effective amount of ADPR, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopologue, or polymorph thereof.
A method for treating, managing, or preventing a disease or condition associated with p53 deficiency in a patient, said method comprising administering to the patient an effective amount of ADPR, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopologue, or polymorph thereof wherein the patient has or is at risk of developing a disease or condition associated with p53 deficiency.
Dependencies are inferred from the claim text.